Evidence map›Paper›PMID 39607862›Full record

ArticleThe oncologist2025

Patients' psychosocial attributes and aggressiveness of cancer treatments near the end of life.

Léa Restivo, Philippe Rochigneux, Anne-Déborah Bouhnik, Thomas Arciszewski, Aurélie Bourmaud, Géraldine Capodano, Agnès Ducoulombier, Julien Mancini, Florence Duffaud, Anthony Gonçalves and 2 more

Abstract read
In one paragraph

Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Léa RestivoAix Marseille University, LPS, Aix-en-Provence, France.ORCID 0000-0003-3568-007X
Philippe RochigneuxMedical Oncology Department, Paoli-Calmettes Institute, Marseille, France.
Anne-Déborah BouhnikAix Marseille University, Inserm, IRD, ISSPAM, SESSTIM, Sciences Economiques and Sociales de la Santé & Traitement de l'Information Médicale, F-13009 Marseille, France.
Thomas ArciszewskiPSYCLE - Aix Marseille University.
Aurélie BourmaudClinical Epidemiology Unit, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris and Inserm CIC 1426, Paris, France.
Géraldine CapodanoDepartment of Supportive and Palliative Care, Institut Paoli-Camettes, Aix-Marseille Univ, CNRS, INSERM, Marseille, France.
Agnès DucoulombierMedical Oncology Department and Translational Oncology Research Laboratory (LRTO), Antoine Lacassagne Center, Côte d'Azur University, Nice, France.
Julien ManciniAix Marseille University, Inserm, IRD, ISSPAM, SESSTIM, Sciences Economiques and Sociales de la Santé & Traitement de l'Information Médicale, F-13009 Marseille, France.
Florence DuffaudMedical Oncology Department, CHU la Timone, APHM, AMU.
Anthony GonçalvesMedical Oncology Department, Paoli-Calmettes Institute, Marseille, France.ORCID 0000-0001-7570-7439
Thémis ApostolidisAix Marseille University, LPS, Aix-en-Provence, France.
Aurélien ProuxDepartment of Supportive and Palliative Care, Institut Paoli-Camettes, Aix-Marseille Univ, CNRS, INSERM, Marseille, France.

Funding

Institut National du Cancer
6 · The paper itself

Abstract

backgroundWhile the use of chemotherapy near the end of life (EOL) has been identified as a relevant criterion for assessing quality of cancer care and has been estimated as non-beneficial, a trend of aggressiveness in cancer care during the last period of life remains. Both patients' sociodemographic characteristics and physicians' practice setting are associated with this use. The role of patients' psychosocial characteristics has however been understudied. The objectives were to study oncologists' intention to recommend chemotherapy or therapeutic abstention in an EOL patient's case and to examine the factors associated with this decision.

methodsA clinical vignette-based questionnaire survey was conducted. While the case presented to the participating oncologists of a patient with EGFR-mutated lung cancer, progressing after osimertinib, ECOG 3, with leptomeningeal disease (N = 146), was strictly equivalent in terms of medical aspects and age, 4 patients' non-medical characteristics were manipulated: gender, marital status, parenthood, and psychosocial characteristics ("nice" patients, patients "making strong demands," or control patients).

results77.4% of the oncologists surveyed stated that they would recommend chemotherapy in this situation. Only scenarios with nice patients or patients making strong demands were associated with less recommendation of chemotherapy (70.8% for the nice/making strong demands scenarios together vs 87.7%, for the control scenario P = .017). Medical oncologists with previous experience of similar cases were also less keen to recommend chemotherapy (73% vs 100%, P = .007). Of the 76.7% of respondents declaring that they would think of other therapeutic options, 49.1% mentioned "other treatments" without mentioning palliative care.

conclusionDeveloping physicians' awareness of the psychosocial aspects at stake in their medical decisions in these sensitive situations may improve EOL care.

Indexed as

Lung NeoplasmsNeoplasmsTerminal CareAdultAgedFemaleHumansMaleMiddle AgedSurveys and Questionnairescare aggressiveness near the end of lifenon-medical influences on medical decision makingpsychosocial attributes

Identifiers

PMID39607862
PMCPMC11997663

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.